Fig. 6From: The vasculogenic mimicry related signature predicts the prognosis and immunotherapy response in renal clear cell carcinomaMolecular docking pose. Screening of candidate small molecules for target proteins using molecular docking. The figure shows the docking poses of the CDH5 active pocket with Crassifogenin C (A), Episappanol (B), Gnetuhainin D (C), and Sappanone B (D). the MAPK1 active pocket with Isolappaol C (E), Leonoside F (F), Licorice Glycoside B (G), and Littorachalcone (H) in docking poses.MMP9 active pocket with Olivacine (I), Picrasidine I (J), Sagecoumarin (K), and Thalifaretine (L) in docking poses.MMP13 active pocket with Andalasin A (M), Dracunculifoside B (N), Glansreginin B (O) and Monocaffeyltartaric Acid (P) in docking posesBack to article page